Foclivia (adjuvanted egg-based influenza A (H5N1) vaccine)
/ CSL Behring
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 11, 2012
Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus
(clinicaltrials.gov)
- P3 | N=342 | Completed | Sponsor: Chiltern Pesquisa Clinica Ltda | Active, not recruiting ➔ Completed
Trial completion • Cardiovascular • Diabetes • Infectious Disease • Influenza • Metabolic Disorders • Pulmonary Disease • Respiratory Diseases
September 11, 2012
Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus
(clinicaltrials.gov)
- P3 | N=342 | Completed | Sponsor: Chiltern Pesquisa Clinica Ltda | N=500 ➔ 342
Enrollment change • Cardiovascular • Diabetes • Infectious Disease • Influenza • Metabolic Disorders • Pulmonary Disease • Respiratory Diseases
1 to 2
Of
2
Go to page
1